$18.31
4.78% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
JE00BYSS4X48
Symbol
NVCR

Novocure Ltd. Stock price

$19.23
-6.15 24.23% 1M
+1.23 6.83% 6M
-10.57 35.47% YTD
+2.93 17.98% 1Y
-62.63 76.51% 3Y
-58.05 75.12% 5Y
+0.95 5.20% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-2.73 12.43%
ISIN
JE00BYSS4X48
Symbol
NVCR
Sector

Key metrics

Market capitalization $2.08b
Enterprise Value $1.79b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.10
P/S ratio (TTM) P/S ratio 3.60
P/B ratio (TTM) P/B ratio 5.76
Revenue growth (TTM) Revenue growth 14.63%
Revenue (TTM) Revenue $577.74m
EBIT (operating result TTM) EBIT $-150.19m
Free Cash Flow (TTM) Free Cash Flow $-78.21m
Cash position $963.68m
EPS (TTM) EPS $-1.39
P/E forward negative
P/S forward 3.93
EV/Sales forward 3.45
Short interest 5.49%
Show more

Is Novocure Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Novocure Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Novocure Ltd. forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Novocure Ltd. forecast:

Buy
71%
Hold
29%

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
578 578
15% 15%
100%
- Direct Costs 135 135
9% 9%
23%
442 442
17% 17%
77%
- Selling and Administrative Expenses 371 371
1% 1%
64%
- Research and Development Expense 210 210
6% 6%
36%
-139 -139
35% 35%
-24%
- Depreciation and Amortization 11 11
1% 1%
2%
EBIT (Operating Income) EBIT -150 -150
33% 33%
-26%
Net Profit -150 -150
24% 24%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Novocure Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novocure Ltd. Stock News

Positive
Seeking Alpha
about 6 hours ago
NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption challenges due to marginal survival benefits and high costs, impacting market growth. NovoCure's financial health shows sufficient liquidity short-term, but profit margins will compress and S&M costs w...
Neutral
Seeking Alpha
one day ago
NovoCure Limited (NASDAQ:NVCR ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Chairman Ashley Cordova - Chief Executive Officer Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive Vice President & President, NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participa...
Neutral
The Motley Fool
one day ago
Oncology treatment pioneer NovoCure (NVCR) reported mixed fourth-quarter 2024 earnings on Thursday, Feb. 27. Q4 revenue matched analysts' consensus expectations at $161.3 million and jumped 21% year over year.
More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office Jersey
CEO Ashley Cordova
Employees 1,453
Founded 2000
Website www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today